2020-08-21

[#DIV28SUPER] M=?UTF-8?Q?=C3=BCnchhausen_?=syndrome

Here is a link to the  fascinating history of Munchhausen syndrome.
Carl Tishler, Ph.D., ABPP
Adjunct Associate Professor of Psychiatry
The Ohio State University

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2020-08-20

[#DIV28SUPER] Your help is needed again for PhenX COVID-19 Crowdsourcing Effort: Phase II. Response needed by August 24, 2020

Your help is needed again for PhenX COVID-19 Crowdsourcing Effort: Phase II.  Response needed by August 24, 2020.

Help Establish Standard Data Collection Protocols for COVID-19 Research


Phase II Open until Monday, August 24

Contribute to the PhenX COVID-19 Crowdsourcing Effort by participating in a short, anonymous survey. This activity should take you 5 to 10 minutes to complete.

Your response will help PhenX create collections of recommended measurement protocols for COVID-19 research. 

Click here to begin!

With thanks to all who participated in Phase I, here is a preview of the results! 

Top 5 Topics For Researchers:
1.    Racial/Ethnic Disparities
2.    Treatment
3.    Chronic Health Conditions
4.    Government Response
5.    Diagnosis

Top 5 Topics for Non-researchers:
1.    Treatment
2.    Racial/Ethnic Disparities
3.    Chronic Health Conditions
4.    Social Distancing
5.    Sources of Information About COVID-19

Collaborators in the PhenX COVID-19 project include the U.S. National Institutes of Health (NIH) Office of Behavioral and Social Sciences Research (OBSSR), the National Institute of Environmental Health Sciences (NIEHS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Allergy and Infectious Diseases (NIAID), the National Library of Medicine (NLM), and the National Human Genome Research Institute (NHGRI). Disaster Research Response (DR2) serves as a repository for disaster-related data collection tools, including COVID-19 surveys. The PhenX Toolkit is a catalog of recommended measurement protocols suitable for use in a variety of research study designs involving human participants. 

Funding

PhenX is funded by the National Institutes of Health (NIH) Genomic Resource Grant (U41HG007050) from the National Human Genome Research Institute (NHGRI) with current or prior funding support from the National Institute on Drug Abuse (NIDA), the Office of Behavioral and Social Sciences Research (OBSSR), the National Institute of Mental Health (NIMH), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Minority Health and Health Disparities (NIMHD), and the Tobacco Regulatory Science Program (TRSP).

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

2020-08-17

[#DIV28SUPER] Call for Nominations - Clinical Practice Guideline Development Panel for Treatment of PTSD in Adults: An Update

—Call for Nominations—

 

Clinical Practice Guideline Development Panel for Treatment of Posttraumatic Stress Disorder (PTSD) in Adults: An Update

 

Nominations must be received by Sept. 28, 2020.

 

The American Psychological Association’s (APA) Advisory Steering Committee for the Development of Clinical Practice Guidelines is seeking nominations of individuals to serve on a guideline development panel that will produce an updated version of APA’s 2017 Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. The Advisory Steering Committee seeks to produce an updated version that will be approved as policy by the APA Council of Representatives by 2022 or as soon as feasible, in keeping with the widely accepted recommendation that clinical practice guidelines be considered for updating at least every five years.

 

Individuals, including those from disciplines outside of psychology and members of the broader community who are affected by PTSD, are encouraged to self-nominate. Nominees who will enhance the diversity of the panel membership and the perspectives represented on the panel are particularly encouraged to apply. Individuals who previously served on the guideline development panel that produced the 2017 guideline are eligible to be considered.

 

The panel will be composed of seven or more members. They will include:

 

  • Researchers and practitioners from psychology and other disciplines with expertise or experience related to the treatment of PTSD in adults.
  • One or more community members who have been treated for PTSD or have had experience interacting with, supporting, or advocating for people who have been treated for PTSD.
  • An individual whose primary expertise lies in research methods, conduct of systematic reviews, and/or guideline development.

 

Nominees’ materials will be initially reviewed by the Advisory Steering Committee, and appointments to the panel will be made by APA’s Board of Directors. One member of the panel will be designated as the chair. Appointments will be contingent on a review of nominees’ potential conflicts of interests. Membership in APA is not a requirement to serve on the panel.

 

The panel will update the 2017 guideline’s recommendations based on current systematic reviews of the research literature as well as other literature and information, in a manner consistent with current best practices for updating clinical practice guidelines. The panel will not itself conduct systematic reviews but will utilize existing reviews and/or solicit new reviews, with the guidance of the Advisory Steering Committee and potentially other consultants. The panel will also update the organization and text of the guideline document in accord with guidance from the Advisory Steering Committee and other sources. Moreover, the panel will solicit and respond to public comments on a draft version of the document.

 

The panel’s work is expected to take approximately two years. Progress reports will be provided to the Advisory Steering Committee, Board of Directors, Council of Representatives, and APA governance groups on a regular basis. The panel’s activities will be supported by designated APA staff.

 

Panel members should have expertise or experience in one or more of the following areas:

 

  • Treatment of PTSD
  • Clinical practice guideline development
  • Comparative effectiveness research
  • Systematic reviews
  • Design and conduct of clinical trials
  • Contemporary methods for evaluation of psychological, behavioral, or pharmacological interventions
  • Dissemination/implementation research
  • Relevant expertise in research design and statistical analysis
  • Experience applying clinical practice guidelines in practice settings
  • Experience using or providing training in evidence-based practices
  • Direct provision of psychological or medical care in diverse practice settings or with diverse populations
  • Patient/consumer perspectives
  • Federal agency policies and programs related to clinical practice guidelines
  • Health care systems administration
  • Public health research and applications
  • Public and community health delivery systems

 

It is anticipated that the members of the panel will collectively have experience working with a broad range of populations (including those described on such dimensions as race/ethnicity, socioeconomic status, culture, language, gender, sexuality, and physical and mental abilities) and in a broad range of settings.

 

Panel members will be expected to commit to the following:

 

  • Attend at least two meetings each year (meetings will be held either virtually or in person in Washington, DC, and will be scheduled after the panel is constituted).
  • Actively participate in monthly telephone conference calls as well as email communications.
  • During some periods, commit several hours per week to assessing systematic reviews and related literature and to writing or revising sections of the guideline document.
  • Respond to emails and requests for information from fellow panel members and APA staff throughout the guideline update process.
  • Willingness to serve for two years (or until the guideline update is complete).

 

Interested individuals should nominate themselves. Your nomination materials should include a cover letter indicating your willingness to serve for two years (or until the guideline update is complete), a brief statement of your specific expertise and qualifications related to the criteria described above, and a current resume/curriculum vitae.

 

Current members of the following APA governance groups that have oversight of APA guideline activities are not eligible to serve on the panel: Board of Directors, Board of Professional Affairs, and Board of Scientific Affairs.

 

In general, individuals may serve on only one active APA clinical or professional practice guideline development panel at a time, although they may serve on more than one over the course of time.

 

Please email all nominations and supporting materials to the APA Clinical Practice Guidelines mailbox (cpg@apa.org) by 11:59 p.m. (ET) Sept. 28, 2020. In the event of questions or difficulties regarding email transmissions, please contact Jacob Marzalik, MA, project manager for APA clinical practice guidelines at jmarzalik@apa.org.

 

Background Information:

 

 

Jacob S. Marzalik, MA

Project Manager, Clinical Practice Guidelines

Practice Transformation and Quality, Practice Directorate

American Psychological Association

 

750 First Street NE, Washington, DC 20002-4242

202-336-5872

 

All APA staff are teleworking until further notice and are experiencing a high volume of inquiries related to COVID-19. For immediate information and resources, visit APA's COVID-19 page for psychologists, health-care workers, and the public.

 

2020-08-13

[#DIV28SUPER] NIDA Neuroscience Update, August 13, 2020

 

Table of Contents

I.   Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)

 

II. Upcoming NIH virtual events on data analysis and interpretation

 

III. Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)

 

IV. Notice to Add a Receipt Date to RFA-DA-21-019 “Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)”

 

V. Notice of Change to RFA-DA-21-005 "Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)"

 

VI. Biomedical Data Repository (U24 – Clinical Trials Not Allowed) – PAR-20-089

 

VII. Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed) – PAR-20-097

I.Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)

https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html

This is an unique “emergency” solicitation to develop the surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions with a high density of individuals who are together for prolonged periods of time. The timeline for award is extremely fast, with earliest starting date in November 2020, in just four months.

Please see below the description of NIDA interest: 

 National institute on Drug Abuse (NIDA)

NIDA has previously supported several surveillance technologies initially intended for drug and overdose detection that could be amenable for real-time, spatially selective, early detection of COVID-19. NIDA is interested in adapting the technologies to the current needs of the communities struggling with the substance use disorders (SUD) that are disproportionally affected by COVID-19, including residents of in-patient SUD treatment facilities. Despite the recent favorable changes in some policies related to the outpatient vs. inpatient treatment options, for many SUD patients the outpatient measures are not considered an adequate clinical option (e.g. life-threatening situations for people at high risk for overdose or complications from withdrawal). Inpatient/residential programs that need to remain open during the current COVID-19 related emergency have been advised to follow the Centers for Disease Control and Prevention guidance on precautions in admitting new patients, management of current residents who may have been exposed to or who are infected with COVID-19, and visitor policies. NIDA is particularly interested in surveillance platforms that would specifically address the needs of the SUD inpatient/residential programs with the focus on admitting new patients during the pandemic and providing uninterrupted services to the current residents.

Please contact:

Elena Koustova; Elena.koustova@nih.gov; 301-496-8768

------------

II. Upcoming NIH virtual events on data analysis and interpretation:

  • Adolescent Brain Cognitive Development (ABCD) Study – ReproNim Virtual Course October – February, 2021. The ABCD-ReproNim Course provides a comprehensive background to data from the ABCD Study® while delivering hands-on, interactive instruction to enable rigorous and reproducible data analyses (see attached flyer). The course runs from October – February and is targeted to students, postdocs, and early career faculty. Visit the ABCD-ReproNim website for more information and to apply.
  • Beyond Statistical Significance: Understanding Meaningful Effects Virtual Workshop September 2. An inherent consequence of large, observational studies is that although effects may be statistically significant, they may only account for a small proportion of the variance. The objective of this workshop is to develop best practice recommendations for interpreting  effects in “big data” by engaging scientists from a range of disciplines in discussions of meaningful science that go beyond statistical significance. Visit the meaningful effects meeting website for more information and to register. 

 

For more information contact

 

Elizabeth A. Hoffman, Ph.D.

Scientific Program Manager, Adolescent Brain Cognitive Development (ABCD) Study

Division of Extramural Research

National Institute on Drug Abuse, NIH

6001 Executive Blvd. Room 4245

Bethesda, MD 20892-9550

Email: elizabeth.hoffman@nih.gov

Office: 301-594-2265

Cell: 240-461-3684

 

III.Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/pa-files/PAR-20-182.html

Due date:  October 30, 2020

NIDA intends to commit $2M in FY2021 to fund 1-3 awards.

 

IV. Notice to Add a Receipt Date to RFA-DA-21-019 “Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)” 

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-019.html

Due date:  July 2021

NIDA intends to commit $4M in FY2022 to fund 1-4 applications

 

V. Notice of Change to RFA-DA-21-005 "Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)"

https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-056.html

Due Date: August 2021

NIDA intends to commit $3M in FY2022 to fund 5-8 awards.

 

VI. Biomedical Data Repository (U24 – Clinical Trials Not Allowed) – PAR-20-089

https://grants.nih.gov/grants/guide/pa-files/PAR-20-089.html

Earliest Submission Date: August 25, 2020

Purpose: This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software or tool development are not appropriate for this activity.

 

VII. Biomedical Knowledgebase (U24 – Clinical Trials Not Allowed) – PAR-20-097

https://grants.nih.gov/grants/guide/pa-files/PAR-20-097.html

Earliest Submission Date: August 25, 2020

Purpose: This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

2020-08-11

[#DIV28SUPER] Fwd: Addressing the Twin Challenges of Substance Use Disorders and COVID-19





Learn more about the problem and possible solutions from NIH's top expert on substance use disorder
Blog

Posted on August 11th, 2020 by Dr. Francis Collins

SARS-CoV-2

Addressing the Twin Challenges of Substance Use Disorders and COVID-19

The coronavirus disease 2019 (COVID-19) pandemic is having a wide range of negative impacts on people affected by a variety of health conditions. Among the hardest hit are individuals struggling with substance use disorders, with recent data indicating that suspected drug-related overdoses and deaths are on the rise across the...

Read More ...

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2020-08-10

[#DIV28SUPER] Your help is needed to establish standard data collection protocols for COVID-19 Research. Response needed by Close of Business August 11!

Dear Colleague,

 

Your help is needed to establish standard data collection protocols for COVID-19 Research.  Contribute to the PhenX COVID-19 Crowdsourcing Effort by participating in a short, anonymous survey, an effort supported by NIH. This activity should take you 5 to 10 minutes to complete. Please take a moment to complete now. Your response will help PhenX create collections of recommended measurement protocols for COVID-19 researchClick here to begin!  Please respond by Close of Business Aug 11. 

 

 

 

More about PhenX toolkit.

 

The PhenX Toolkit (consensus measures for Phenotypes and eXposures) provides recommended standard data collection protocols for conducting biomedical research. The protocols are selected by Working Groups of domain experts using a consensus process, which includes the scientific community. The Toolkit provides detailed protocols for collecting data and tools to help investigators incorporate these protocols into their studies. Using protocols from the PhenX Toolkit facilitates cross-study analysis, potentially increasing the scientific impact of individual studies.

 

Collaborators in the PhenX COVID-19 project include the U.S. National Institutes of Health (NIH) Office of Behavioral and Social Sciences Research (OBSSR), the National Institute of Environmental Health Sciences (NIEHS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Allergy and Infectious Diseases (NIAID), the National Library of Medicine (NLM), and the National Human Genome Research Institute (NHGRI). Disaster Research Response (DR2) serves as a repository for disaster-related data collection tools, including COVID-19 surveys. The PhenX Toolkit is a catalog of recommended measurement protocols suitable for use in a variety of research study designs involving human participants. https://www.phenxtoolkit.org/about

 

Funding

PhenX is funded by the National Institutes of Health (NIH) Genomic Resource Grant (U41HG007050) from the National Human Genome Research Institute (NHGRI) with current or prior funding support from the National Institute on Drug Abuse (NIDA), the Office of Behavioral and Social Sciences Research (OBSSR), the National Institute of Mental Health (NIMH), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Minority Health and Health Disparities (NIMHD), and the Tobacco Regulatory Science Program (TRSP).

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

2020-08-06

[#DIV28SUPER] FW: Updates on how APA 2020 Virtual works and how to access divisional material

Some great tips from Susan Collins (Division 50 program chair) on how to access the virtual convention content. Sounds like with everyone on their all at once (there's over 13000 registrants), there is some lag in the servers right now, but that's the benefit of having the content up there for one year :)

Best,
Justin

---------------------------------------------------------
Justin C. Strickland, Ph.D.
Postdoctoral Fellow
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Phone: (410) 550-1975

Begin forwarded message:

From: "Collins, Susan" <susan.collins@WSU.EDU>
Subject: [DIVISION] FW: Updates on how APA 2020 Virtual works and how to access div 50 material
Date: August 6, 2020 at 12:07:39 PM EDT
Reply-To: "Collins, Susan" <susan.collins@WSU.EDU>


      External Email - Use Caution      



Here's what I just sent to div 50 to help walk people thru…
S
 
-----------
Susan E. Collins, PhD (she/her)
Licensed clinical psychologist (PY60203080)
Codirector, Harm Reduction Research and Treatment (HaRRT) Center
Professor, Department of Psychology, Washington State University
Affiliate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine
Adjunct Affiliate Professor, Department of Psychology, University of Washington
 
I acknowledge that I live and work on the homelands of the Coast Salish (UW), Spokane and Nimiipuu - Nez Perce tribes and Palus people (WSU).
I acknowledge the legacy of violence and displacement of settler colonialism on which my institutions are built and from which I have unjustly benefited.
I pledge to move forward in a better way to #HonorNativeLand, and I support www.realrentduwamish.org.
 
From: Collins, Susan 
Sent: Thursday, August 6, 2020 9:06 AM
To: DIV50DISCUSS@LISTS.APA.ORG
Subject: Updates on how APA 2020 Virtual works and how to access div 50 material
 
Hi all,
 
Good morning and welcome to APA 2020 Virtual Convention! The convention "Main Stage" and Division 50 content is now available. I will say, the system has been VERY sticky this morning, so be patient as each page will have a delay until you see options/can click. While you wait, do some breathing exercises, grab a coffee, pet the dog, watch the main stage session with Soledad O'Brien   It might take a bit, but it does eventually work. I assume this is because so many are logging on at the same time.
 
To get to the Division 50 content (they don't make it easy ðŸ˜‰):
  1. You should have received an email after you registered that gives you your "on-demand" login and password. Hold on to that.
  2. Go to www.convention.apa.org. And click on the button that says "Join APA 2020 Virtual."
  3. Click on the button that says "On Demand."
  4. From there or before you access programming, you might be prompted to enter your on-demand login and password. That's the one you received in the APA email.
  5. Pause, take a breath, get some coffee while it loads. Then, scroll down a little and you will see buttons including "Search by Division" or "Search by author" – you can do either, of course.
  6. If you click on "search by division," you will have Div 1 as the default. You will click arrow down to find and click on "Division 50"  and you will have pulled up all of our posters, symposia, skill-building sessions. 
  7. As you scroll down you will see first posters, skill-building sessions and then symposia. And you can click on the screen with the arrow to play that content.
 
Please scroll down to see how things work for accessing all the convention content. This is basically the information in the email you will receive when you register.  
If you have technical difficulties that are not resolved with the below, APA 2020 Virtual Registration and Login help is available at convention@apa.org or you can call: 202-336-6020 or 202-336-5580.
Thanks, all!
Susan
 
 
 

*** Please do not reply to this e-mail. It was sent from an automated system. ***

Welcome to APA 2020 Virtual!
We are so glad you are joining us for APA 2020 Virtual, the first all-virtual convention of the American Psychological Association. Please review the following information carefully and keep it close at hand so you can have a seamless APA 2020 Virtual experience.
Starting at 10:30 am ET August 6, 2020, you will be able to enter APA 2020 Virtual atconvention.apa.org
To experience the full event, you will need to use two logins. The APA 2020 Virtual Platform uses cookies to save your logins. Please note that these cookies expire after 24 hours and you may need to login again each day.
Main Event Login
After clicking on the link at convention.apa.org, you will be asked to use the login information you used to register for the event.

On-Demand Login
To access the "on-demand" portion of the event, you will need to use the following login details. The on-demand portion houses the more than 3,000 sessions, posters and discussions that are available to attendees for on-demand viewing.
Note: You cannot reset this password. Please retain this information until August 1, 2021.
Username: [your email address should appear here]
Password: [password should appear here]
This is case sensitive

Optional — Zoom Login
Some of our live events will be housed in Zoom for the best interactive experience. Although it is not required, for the most seamless experience, we recommend you register for a Zoom account in advance. Note: APA is unable to provide support for Zoom technical issues.
How to Experience APA 2020 Virtual
To make sure you are prepared for the event, please visit the attendee guide. This has information about navigating the APA 2020 Virtual platform, the technical requirements, and how to get support. 
Troubleshooting and Help
There are lots of ways to get help if you run into issues. 
APA 2020 Virtual Registration and Login*
convention@apa.org
Call: 202-336-6020 or 202-336-5580 
APA Membership Status*
convention@apa.org
Call: 202-336-6020 or 202-336-5580 
Issues within the APA 2020 Virtual Scheduled Events
Click on "Help" at the top of the homepage. You will access a chat box where you can talk to a support person. 
*Our team is available from 9am-5pm ET. You may experience some delay outside of those hours. 
Note: APA is unable to provide support for Zoom technical issues. 

 
Click on this link to unsubscribe from the DIVPCHAIRSEVEN list UNSUBSCRIBE

An email will automatically open with "Unsubscribe" in the subject area. Just Send the message, as is, to unsubscribe from this list.


2020-08-05

[#DIV28SUPER] Hiring two tenure-track faculty

Sharing this job announcement for a colleague:

Faculty Positions at the Health Promotion Research Center

 

The newly renamed Health Promotion Research Center (HPRC; formerly the Oklahoma Tobacco Research Center) of the NCI Designated Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center (OUHSC) is seeking applications for 2 tenure-track faculty positions at the Assistant / Associate/Full Professor level. Research focus in one or more of the following areas is preferred:

 

  • Health behavior change interventions (e.g., smoking cessation, other substance use cessation, increasing physical activity, improving diet)
  • Tobacco regulatory science
  • Assessment of and interventions focused on opioid misuse
  • Mobile health
  • Multiple health behavior change

 

These faculty positions are hard money, offer extremely competitive salaries, and come with very generous start-up packages. Rank to be commensurate with qualifications and experience. Successful applicants at the Assistant Professor level will have a strong academic record, with evidence of scholarship and show strong potential for acquiring extramural funding. Applicants at the Associate or Full Professor level should have a strong record of extramural funding. Applications will be reviewed as they are received. Leadership opportunities are available based upon interest and qualifications.

 

The mission of the HPRC (http://otrc.stephensoncancercenter.org) is to reduce the burden of disease by addressing a broad range of modifiable health risk factors, including tobacco use, sedentary lifestyle, poor diet, and risky alcohol and other substance use through research, novel intervention development, and dissemination of research findings. The HPRC contains four major resources that facilitate research, which are led by HPRC faculty: 1) the Tobacco Treatment Research Program (TTRP), 2) the Mobile Health Shared Resource, 3) the Tobacco Regulatory Science Lab, and 4) the Post-Doctoral Fellowship Training Program (see https://otrc.stephensoncancercenter.org/Training).

 

Since 2017, the TTRP has provided cessation services to over 1000 adults seeking smoking cessation treatment and has supported recruitment for 7 tobacco-related studies. Many of these studies test novel smoking cessation interventions for underserved adults.

 

Over the past 4 years, we have developed the InsightTM mHealth Platform which enables researchers to rapidly (i.e., within 1-2 weeks) create smartphone-based research studies that may include ecological momentary assessments and sensor data (i.e., activity monitor, mobile carbon monoxide monitor) to identify environmental, cognitive, affective, physiological, and behavioral antecedents of health risk behaviors and deliver context-specific adaptive interventions in real-time. The mHealth resource is currently staffed by 7 computer scientists/engineers and 4 additional staff members. To date, the mHealth resource has supported approximately 50 studies worth over $30 million in total costs including 25 studies that were funded by the NIH. See more here: https://otrc.stephensoncancercenter.org/Mobile-Health-Technology

 

The Tobacco Regulatory Science Lab space (1,012 square feet) is specifically designed for the observation and assessment of smoking and other tobacco use behavior. It includes four negative pressure rooms and two control rooms for conducting clinical human laboratory research. This space is configured to enable collection and processing of participant saliva, blood, urine, and buccal samples. Since its inception, the laboratory has supported numerous NIH-funded grants from the Food and Drug Administration Center for Tobacco Products.

 

The NCI Designated SCC is Oklahoma's only academic cancer center. With a well-developed and supportive infrastructure and over 200 members from the University of Oklahoma Health Sciences Center, the Oklahoma Medical Research Foundation and several other entities, the SCC places a high priority on promoting translational research that moves research ideas into clinical applications.

 

Oklahoma City is the anchor of a rapidly growing, multicultural metropolitan area with a population of 1.3 million, over 300 days of sunshine annually, very affordable cost of living, excellent schools and a wide array of cultural amenities.

 

Applicants should email a cover letter (stating qualifications, overview of professional goals, and research interests) and curriculum vitae to Michael Businelle, PhD at Michael-businelle@ouhsc.edu.

 

The University is an EO/AA institution. Individuals with disabilities and protected veterans are encouraged to apply.





Best,


Casey Guillot, PhD

Assistant Professor of Psychology

Behavioral Science Program

University of North Texas


Office: Terrill Hall 382

Phone: 940-369-8426

Lab Website: http://psychology.unt.edu/disposition-emotion-addiction-research-dear-laboratory